Viruses are the tinier germs that can cause several infectious diseases such as flu, common cold, and warts. Viruses can also cause severe illnesses, including smallpox, HIV/AIDS, and Ebola. Viruses reproduce inside cells and able to enter into any living, healthy cells and multiply and produce other viruses like themselves. Different viruses attack specific cells in the body such as liver, brain, skin, blood and also reproductive, respiratory, and gastrointestinal systems.
New Intelligence Report on “Antiviral Drug Resistance Market to 2027” is recently published by The Insight Partners. The report aims to provide leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years
According to a new market research study titled ‘Antiviral Drug Resistance Market to 2027 – Global Analysis and Forecasts by Product, Disease Indication, Technology, and End User.’ The global antiviral drug resistance market is expected to reach US$ 4,573.2 Mn in 2027 from US$ 2,572.3 Mn in 2018. The market is estimated to grow with a CAGR of 6.8% from 2019-2027. The report highlights the trends prevalent in the global antiviral drug resistance market and the factors driving the market along with those that act as deterrents to its growth.
Get Sample PDF Copy at https://www.theinsightpartners.com/sample/TIPRE00006395
Antiviral Drug Resistance Market to 2027 - Global Analysis and Forecasts By Product (Kits & Reagents and Instruments), Disease Indication (Human Immunodeficiency Virus [HIV], Hepatitis and Cytomegalovirus [CMV]), Technology (Immunodiagnostics, Polymerase Chain Reaction [PCR], Next Generation Sequencing [NGS], and Other Technologies), End User (Hospitals & Clinics, Pathology or Diagnostic Laboratories and Research Institutes), and Geography
The major players operating in the antiviral drug resistance market include, Danaher, Abbott, BD, F. Hoffmann-La Roche Ltd, Trinity Biotech, Seimens AG, bioMérieux SA, Bio-Rad Laboratories, Inc, AccuBioTech Co., Ltd., and ACON Laboratories, Inc.. The market has witnessed various organic as well as inorganic developments during recent years in the antiviral drug resistance market. During July 2019, Roche expanded its Global Access Program beyond HIV, to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low and middle income country programs. These strategies are anticipated to drive growth of the company during the forecast period.
The prevalence of virus infections such as hepatitis has increased during recent years across the globe. Hepatitis causes liver damage and inflammation that can also damage other organs. It is a major global health problem that can cause chronic infection and also upsurge the higher risk of death from cirrhosis and liver cancer. Hepatitis can be categorized as hepatitis A, B, C, D, and E that spread through different causes. According to the WHO (World Health Organization), the prevalence of Hepatitis B is the highest in the African and Western Pacific Region, where 6.1% and 6.2% of the adult population is infected respectively.
The increasing healthcare expenditure in the emerging economies such as Asia Pacific and South and Central America are enabling the researchers to develop treatment options for a wide range of viral diseases by utilizing advanced techniques such as PCR (Polymerase Chain Reaction), next generation sequencing and others. The viral infectious diseases is anticipated to remain a major public health problem in the coming decades, which poses a threat to both national and international health security. Endemic diseases including, human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) will continue to challenge public health. For the early detection and rapid response, high level of awareness is required across the region. Thus, the rapid growth and innovations coming from the emerging nations are expected to increasing the growth opportunities and sales in the global antiviral drug resistance market.
Buy Complete Report at https://www.theinsightpartners.com/buy/TIPRE00006395
Contact us –
Phone : +1-646-491-9876
Email Id : email@example.com
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Media, Healthcare and Telecommunication industries.